LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMAPier Luigi Zinzani, M. Hamadani, Juan Pablo Alderuccio et al.|Hematological Oncology|2021Cited by 8
LONG‐TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS‐2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMAPaolo F. Caimi, Carmelo Carlo‐Stella, Weiyun Z. Ai et al.|Hematological Oncology|2023Cited by 1